Whole-Cell Patch-Clamp Recording of Evoked AMPA/NMDA Ratio at CA1 Schaffer Collateral Synapses in Acute Mouse Hippocampal Slices

Whole-cell voltage-clamp recordings from CA1 pyramidal neurons in acute 300 µm transverse hippocampal slices. Each experimental group requires n = 12-15 cells from at least 5 animals (no more than 3 cells per animal to limit pseudoreplication). Cells are assigned to conditions by animal genotype/treatment, with the experimenter blinded to genotype during recording and analysis via coded slice labels. AMPA EPSCs recorded at -70 mV (average of 20-30 sweeps, 0.1 Hz), then NMDA component measured at +40 mV. Recordings span P28-P42 to control developmental synapse maturation. A single stimulus intensity yielding ~100-200 pA AMPA EPSC is used per cell.

BSL-1; rodent tissue handling under IACUC-approved protocol. Hazards: QX-314 and picrotoxin are neurotoxic — wear nitrile gloves, avoid aerosols, and dispose in designated chemical waste. D-AP5/NBQX are receptor antagonists handled similarly. CsMeSO3 and Cs salts are irritants. Sharp vibratome blades and pulled glass pipettes are physical hazards (use blade guards, sharps container). Compressed O2/CO2 gas cylinders secured and regulated. Animal carcasses disposed per institutional biohazard policy.

Positive/validation control: bath application of 50 µM D-AP5 must abolish the NMDA component (current at +40 mV, 50 ms post-stimulus), confirming receptor identity. Negative control: in a subset of cells, application of 10 µM NBQX should abolish the fast inward AMPA current at -70 mV. Internal control: QX-314 in the pipette blocks postsynaptic Na+ channels and unclamped action potentials. Series-resistance control: cells with Ra drift >20% or >25 MΩ are discarded. Vehicle control slices (DMSO-matched) are required whenever a drug dissolved in DMSO is part of the experimental arm.

Healthy recordings show stable, monophasic AMPA EPSCs (100-200 pA) at -70 mV with rapid rise (<2 ms) and decay (~5-8 ms). At +40 mV a slow, outward, AP5-sensitive NMDA component is present. Typical control AMPA/NMDA ratio at CA1 in juvenile mice is ~1.5-2.5. An LTP or stimulant-exposure effect would shift the ratio upward by 30-60% (e.g., 2.0 → 2.8-3.2). Ra should remain <25 MΩ and Rm > 100 MΩ throughout.

• Cutting aCSF (sucrose-based, in mM): 87 NaCl, 75 sucrose, 25 NaHCO3, 25 glucose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2; osmolarity 315-325 mOsm, bubbled with 95% O2/5% CO2
• Recording aCSF (in mM): 125 NaCl, 25 NaHCO3, 25 glucose, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2; 300-310 mOsm
• Cesium-based internal solution (in mM): 130 CsMeSO3, 8 NaCl, 10 HEPES, 0.5 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 5 QX-314 chloride, 10 phosphocreatine; pH 7.3 with CsOH, 290-295 mOsm
• Picrotoxin (100 µM, GABA-A blocker) in recording aCSF
• Borosilicate glass capillaries (1.5 mm OD, 0.86 mm ID, filament)
• C57BL/6J mice, P28-P42
• Concentrated isoflurane or ketamine/xylazine for anesthesia
• 0.4% trypan blue (optional, slice viability check)

To measure evoked excitatory postsynaptic currents (EPSCs) from CA1 pyramidal neurons in voltage-clamp mode and compute the AMPA/NMDA ratio by isolating the AMPA component at -70 mV and the NMDA component at +40 mV (50 ms post-stimulus). This provides a sensitive, intra-cell-normalized index of postsynaptic receptor composition that disambiguates pre- versus postsynaptic changes in synaptic efficacy following experimental manipulations such as fear conditioning, drug exposure, or genetic perturbation.

1. Anesthetize mouse with isoflurane, confirm loss of pedal reflex, and rapidly decapitate per IACUC protocol.
2. Extract brain into ice-cold (0-4 °C) oxygenated sucrose cutting solution within 60 s.
3. Block the brain, mount, and cut 300 µm transverse hippocampal slices on a vibratome (0.10 mm/s advance, 1.0 mm amplitude) in ice-cold cutting solution.
4. Transfer slices to a holding chamber with recording aCSF at 32-34 °C for 30 min, then hold at room temperature (22-24 °C) for ≥45 min before recording.
5. Transfer one slice to the recording chamber; perfuse with oxygenated recording aCSF + 100 µM picrotoxin at 2-3 mL/min, 30-32 °C.
6. Pull patch pipettes to 3-5 MΩ; fill with Cs-internal.
7. Place a bipolar stimulating electrode in stratum radiatum ~150 µm from the recording site to activate Schaffer collaterals.
8. Form a >1 GΩ seal on a CA1 pyramidal soma, break in, and hold at -70 mV. Reject cells with Ra > 25 MΩ or that drifts >20%.
9. Set stimulus intensity (0.1 ms pulse, 0.1 Hz) to evoke a 100-200 pA AMPA EPSC; record 20-30 sweeps.
10. Step holding to +40 mV, wait 3-5 min for equilibration, record 20-30 sweeps.
11. Apply 50 µM D-AP5 at the end to confirm the +40 mV late component is NMDA-mediated (it should be abolished).

Independent variable: experimental treatment/genotype (e.g., LTP-induced vs. naive, drug vs. vehicle). Dependent variable: AMPA/NMDA ratio (peak AMPA current at -70 mV divided by NMDA current at +40 mV measured 50 ms after stimulus onset). Controlled variables: animal age (P28-P42), slice thickness (300 µm), recording temperature (30-32 °C), holding potentials (-70 / +40 mV), stimulus intensity normalized to AMPA EPSC amplitude, Ra (<25 MΩ), internal/external solution composition, and time post-dissection (45 min-6 h).

We hypothesize that experimental conditions which drive postsynaptic AMPA receptor insertion (e.g., LTP induction or chronic stimulant exposure) will increase the AMPA/NMDA ratio relative to control, whereas conditions causing synaptic depression will decrease it. Because the ratio is computed within each cell, presynaptic release-probability changes and slice-to-slice variability in stimulation should not systematically bias the metric, isolating a postsynaptic locus of change.

Acquire at 10-20 kHz, filter at 2-4 kHz. Average the 20-30 sweeps per holding potential in Clampfit, pClamp, or Stimfit/Python. AMPA amplitude = peak inward current at -70 mV measured from a 5 ms pre-stimulus baseline. NMDA amplitude = mean current in a 2 ms window centered 50 ms after stimulus at +40 mV (a time at which AMPA current has decayed). Compute AMPA/NMDA per cell. Exclude cells failing Ra/Rm criteria before unblinding. Report per-cell ratios and animal-level means.

1. No seal / unstable seal: re-filter internal, ensure pipette tip is clean, increase positive pressure on approach, and verify osmolarity (290-295 mOsm). 2. Rapidly rising Ra: pipette tip clogging — increase tip size to 3-4 MΩ or reposition; re-break-in gently. 3. Polysynaptic/epileptiform EPSCs: confirm 100 µM picrotoxin present; reduce stimulus intensity; cut a knife nick between CA3 and CA1. 4. No NMDA component at +40 mV: verify Mg2+ removal is not needed (it isn't at +40 mV), check QX-314 is included, confirm holding actually reached +40 mV (Ra error), and verify AP5 sensitivity. 5. Run-down of EPSC over time: ensure fresh Mg-ATP/Na-GTP in internal (keep on ice, use within 4 h), limit recording to <20 min after break-in.

Compare two groups with a nested/hierarchical mixed-effects model (cell nested within animal) or, if pseudoreplication is controlled by averaging to animal level, an unpaired two-tailed t-test (alpha = 0.05). For >2 groups use one-way ANOVA with Tukey HSD correction. Power analysis: detecting a 30% ratio difference (effect size d ≈ 1.0, SD ~0.5) at 80% power, alpha 0.05, requires n ≈ 12-15 cells/group. Report exact n for both cells and animals.